Refine by
Neuromuscular Articles & Analysis
30 news found
AskBio has been driving Bayer’s pipeline of investigational novel gene therapies that are developed across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications. ...
ByBayer AG
The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure. ...
ByBayer AG
The company’s 1st-in-class gene therapy (ET-101) has been engineered to overexpress Caveolin-1, which organizes and regulates synaptic receptors essential for neuromuscular signaling and function. Eikonoklastes is also advancing a new generation of tissue factor (TF) therapies (ET-201) for the treatment of Triple Negative Breast Cancer and other oncology indications. ...
MVP is MDA’s drug development program, which is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular disorders. MVP evaluates and makes targeted investments in for-profit and not-for-profit companies and academics developing therapeutics. ...
BynVector
Brandon Nokes, Professor Atul Malhotra, and other collaborators, is based on a post-hoc analysis of 65 participants with mild obstructive sleep apnea (OSA) who completed sleep testing before and after six weeks of genioglossus (tongue muscle) neuromuscular electrical stimulation (NMES) with eXciteOSA. The first of its kind, eXciteOSA is an FDA-authorized, non-invasive daytime ...
PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be included at the 2022 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, being held September 21-24, 2022 in Nashville, TN and virtually. ...
“Pompe disease is a progressive, life-limiting neuromuscular disorder caused by the accumulation of lysosomal glycogen in cardiac and skeletal muscle as well as the CNS. ...
Min served as clinical team lead for more than ten Phase 1 clinical studies, including a pivotal Phase 1 safety study that led to the US approval in 2015 for Bridion®, a drug indicated for the reversal of neuromuscular blockade induced by rocuronium or vecuronium, typically during surgery. ...
While the experts agreed that the ReStore is likely to cost more than the current standard of care, one of the commentators noted the case for cost effectiveness could be proven with evidence the ReStore improved neuromuscular recovery more than standard care, and lowered resource impact. ...
” OSA is a progressive disease, often starting with primary snoring, affecting nearly 1 billion adults aged 30 to 69 globally.1 Used for only 20 minutes per day during the initiation period, and then twice per week thereafter for maintenance, eXciteOSA targets a primary root cause of mild OSA by delivering neuromuscular electric stimulation to increase tongue muscle ...
NDM disorders are a group of rare, inherited neuromuscular disorders which is characterized by the inability to relax muscles following voluntary contraction. ...
” Unlike devices used while patients are asleep, eXciteOSA is the first marketed device designed to be used while awake. It works by applying neuromuscular electrical stimulation (NMES) on the genioglossus muscle – the major muscle that forms the tongue mass. ...
He has worked across multiple therapeutic areas, including neuropsychiatry, neurodegeneration, neuromuscular diseases, and metabolic diseases. He has led more than 20 preclinical programs, successfully advancing a number of these into clinical development. ...
Traditionally, the main goal of BCI has been to replace or restore useful functions to people disabled by neuromuscular disorders. However, recent studies have shown that the technology may have useful applications for mental health disorders as it allows for a direct decoding of emotional experience from neural activity. ...
About Generalized Myasthenia Gravis (gMG) Myasthenia gravis (MG) is a rare, progressive, autoimmune neuromuscular disease. In patients with anti-acetylcholine receptor (AchR) antibody-positive MG, the body’s own immune system over-responds, leading the body to attack its own healthy cells and produce antibodies to fight against AchR, a receptor located on muscle cells at ...
Signifier Medical Technologies, an innovator in the sleep disordered breathing market, today announced that eXciteOSA®, the first and only daytime intraoral neuromuscular stimulation device for treating mild obstructive sleep apnea and snoring, has received the prestigious GOOD DESIGN® Award in the Medical category. ...
Signifier Medical Technologies, an innovator in the sleep disordered breathing market, today announced that eXciteOSA®, the first and only daytime intraoral neuromuscular stimulation device for treating mild obstructive sleep apnea and snoring, has been cleared by the U.S. ...
” eXciteOSA® is the only clinically proven daytime intraoral neuromuscular stimulation device to improve the quality of sleep by reducing sleep apnea and snoring significantly when used for 20 minutes once a day for six weeks1-4. ...
Liberate Medical today announced the results of a second randomized controlled pilot trial of its proprietary medical device, the VentFree Respiratory Muscle Stimulator, the only non-invasive and only breath-synchronized neuromuscular electrical stimulation device used to address respiratory muscle atrophy in mechanically ventilated patients. ...
The VentFree stimulator uses proprietary non-invasive neuromuscular electrical stimulation to contract the abdominal wall muscles in synchrony with exhalation during mechanical ventilation. ...